eCite Digital Repository

Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group

Citation

Talaulikar, D and Tam, CS and Joshua, D and Ho, JP and Szer, J and Quach, H and Spencer, A and Harrison, S and Mollee, P and Roberts, AW and Horvath, N and Lee, C and Zannettino, A and Brown, R and Augustson, B and Jaksic, W and Gibson, J and Kalff, A and Johnston, A and Trotman, J and Kalro, A and Grigoriadis, G and Ward, C and Prince, HM, Treatment of patients with Waldenström macroglobulinaemia: clinical practice guidelines from the Myeloma Foundation of Australia Medical and Scientific Advisory Group, Internal Medicine Journal, 47, (1) pp. 35-49. ISSN 1444-0903 (2017) [Refereed Article]

Copyright Statement

Copyright 2017 Royal Australasian College of Physicians

DOI: doi:10.1111/imj.13311

Abstract

Waldenström macroglobulinaemia (WM) is an indolent B-cell malignancy characterised by the presence of immunoglobulin M (IgM) paraprotein and bone marrow infiltration by clonal small B lymphocytes, plasmacytoid lymphocytes and plasma cells. The symptoms of WM are protean, often follow an asymptomatic phase and may include complications related to the paraneoplastic effects of IgM paraprotein. The revised 2016 World Health Organization classification includes the MYD88 L265P mutation, which is seen in >90% of cases, within the diagnostic criteria for WM. While treatment of WM has often been considered together with other indolent B cell lymphomas, there are unique aspects of WM management that require specific care. These include the unreliability of IgM and paraprotein measurements in monitoring patients prior to and after treatment, the lack of correlation between disease burden and symptoms and rituximab-induced IgM flare. Moreover, while bendamustine and rituximab has recently been approved for reimbursed frontline use in WM in Australia, other regimens, including ibrutinib- and bortezomib-based treatments, are not funded, requiring tailoring of treatment to the regional regulatory environment. The Medical and Scientific Advisory Group of the Myeloma Foundation Australia has therefore developed clinical practice guidelines with specific recommendations for the work-up and therapy of WM to assist Australian clinicians in the management of this disease.

Item Details

Item Type:Refereed Article
Keywords:Waldenström macroglobulinaemia,lymphoplasmacytic lymphoma, rituximab,ibrutinib, bendamustine, monoclonalgammopathy of undetermined significance
Research Division:Medical and Health Sciences
Research Group:Oncology and Carcinogenesis
Research Field:Cancer Therapy (excl. Chemotherapy and Radiation Therapy)
Objective Division:Health
Objective Group:Clinical Health (Organs, Diseases and Abnormal Conditions)
Objective Field:Cancer and Related Disorders
UTAS Author:Johnston, A (Dr Anna Johnston)
ID Code:124596
Year Published:2017
Web of Science® Times Cited:5
Deposited By:Medicine
Deposited On:2018-02-28
Last Modified:2018-09-11
Downloads:0

Repository Staff Only: item control page